miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Apoptosis
Cell Line, Tumor
Cell Proliferation
Colorectal Neoplasms
/ drug therapy
Drug Resistance, Neoplasm
/ genetics
Female
Fluorouracil
/ administration & dosage
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Male
MicroRNAs
/ genetics
Middle Aged
Molecular Targeted Therapy
/ methods
Oxaliplatin
/ administration & dosage
Receptors, CXCR4
/ antagonists & inhibitors
Signal Transduction
5-FU
CXCR4
Colorectal cancer
Oxaliplatin
miR-193a-5p
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
17
10
2020
revised:
26
12
2020
accepted:
26
12
2020
pubmed:
12
1
2021
medline:
29
6
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide. The role of microRNAs (miRNAs/miRs) as small (19-25 nucleotides in length) non-coding RNA molecules that modify gene expression has been shown in several types of cancer. 5-Fluorouracil (5-FU) and oxaliplatin (Ox) are two common chemotherapeutic agents used to treat cancer. The present study aimed to evaluate the expression levels of miR-193a-5p in CRC, and its effect on the C-X-C Motif Chemokine Receptor 4 (CXCR4) target gene alone and in combination with chemotherapeutic drugs, to determine its possible role in chemoresistance. CRC tissues and adjacent non-cancerous tissue were obtained from 67 patients who had undergone surgery to determine the expression levels of miR-193a-5p and CXCR4. Subsequently, qPCR and Western blotting were performed to determine the effect of miR-193a-5p and chemotherapy drugs on CXCR4. َAlso, MTT assay, and flow cytometry was performed to determine their role in cell viability and apoptosis. Besides, the relationship between miR-193a-5p and CXCR4 with patients' clinical features was investigated. The results of the present study showed that miR-193a-5p was significantly downregulated, whereas CXCR4 was significantly upregulated in tumor tissues obtained from patients with CRC compared with the adjacent non-tumor healthy controls. In addition, the upregulation of miR-193-5p reduced the expression levels of CXCR4, particularly in combination with 5-FU and OX. Besides, using rescue experiments, the present study showed that miR-193a-5p replacement was able to suppress CXCR4-induced CRC cell proliferation by directly targeting CXCR4. Furthermore, there was a significant association between miR-193a-5p and CXCR4 with certain clinicopathological characteristics, particularly with metastasis-related features. These results suggest that miR-193a-5p serves a tumor-suppressive function in CRC and can directly target CXCR4 and decrease its mRNA and protein expression levels. Additionally, miR-193a-5p in combination with 5-FU and Ox potentiated reducing CXR4 expression, which may reveal its contribution to tumor chemoresistance. In conclusion, miR-193-5p may be applicable as a prognostic and diagnostic marker, and also serve as a therapeutic factor by reducing CXCR4 in combination with chemotherapeutic drugs.
Identifiants
pubmed: 33429333
pii: S1567-5769(20)33823-6
doi: 10.1016/j.intimp.2020.107355
pii:
doi:
Substances chimiques
CXCR4 protein, human
0
MIRN193 microRNA, human
0
MicroRNAs
0
Receptors, CXCR4
0
Oxaliplatin
04ZR38536J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107355Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.